FDA Warning Letter: Samm Solutions, Inc., d.b.a. BTS Research
type: Action
additional type: https://schema.org/RegulationAction
start time: 2023-10-31
description: Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Issued by FDA Center for Drug Evaluation and Research | CDER on 2023-10-20.
agent: FDA Center for Drug Evaluation and Research | CDER
object: Samm Solutions, Inc., d.b.a. BTS Research
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
source organization: U.S. Food and Drug Administration
publisher: AI Analytics

PropertyValue
property ID: FDA Warning Letter ID
value: 1bc032e423840c43

AI Analytics
type: Organization